Rich Puts Else Nutrition (TSXV:BABY) on FULL ALERT

Else Nutrition

Else Nutrition Holdings Inc. (TSXV:BABY) (OTCPK:BABYF) has become one of Rich’s biggest winners. Since he first profiled the company back in October, BABY has been on a tear, growing from $0.31 on October 17 to $0.89 today. That’s 187% worth of value added in just over three months!

A good deal of that growth arrived in the last week, meaning BABY is in the middle of another big growth spurt. Now, as it nears the $1.00 mark, Rich is putting the stock on full alert.

“I said they’re going to $1.00 because they’re changing the world,”  he says. “When it hits $1.00, they will officially be up 250% since I first brought them to you.”

Else Nutrition’s Latest News

Yesterday, Else announced that it entered into an investment agreement with NewHLimited.

A subsidiary of Health and Happiness International Holdings Limited, which trades on the Hong Kong Stock Exchange, NewHhas agreed to invest C$5.75 million in Else Nutrition. This agreement is part of an aggregate private placement offering of up to C$8.0 million.

Enter Your E-mail Address To Subscribe

* indicates required

Else says that it will use these proceeds to accelerate its US launch in Q2, 2020.

Else will also dedicate the newfound funds to enhancing its toll manufacturing capabilities and to build its distribution relationship with H&H and expedite sales in the new territories. Finally, the company plans to undertake additional marketing initiatives prior to launch.

CEO and Co-Founder of Else Nutrition, Hamutal Yitzhak, says of the agreement:

“We are thrilled about this relationship, and about the strong alignment between Else Nutrition and the H&H group. The strategic alignment with such a reputable, global and premium, health and wellness brand-builder, coupled with the investment, provide growth potential for our brand globally. It marks a significant milestone in our mission to change the way we feed our babies and families for generations to come, using real, clean, plant-based alternatives.”

Else Nutrition Will Operate in Both Infant and Adult Markets

As Rich reported last month, the company received a notice of allowance from the US Patent & Trademark Office to extend its existing patents to cover the adult market for malnutrition.

Else Nutrition’s formula consists of only three primary ingredients: tapioca, almonds, and buckwheat. Because of this, it provides the necessary proteins, amino acids, and other required nutrients for adults who have specific malnutrition-related conditions such as lean body mass and declining basal metabolic rates. And it does all this in a single food serving.

The infant formula market alone is expected to be worth US$103.75 billion by 2026. As Else will provide the only non-dairy, non-soy-based infant formula, it’ll likely capture a sizeable portion of the market.

In addition, it’s made using a clean, chemical-free process. This keeps the formula free of GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens.

BABY’s formula is the best choice for health-conscious parents and adults with malnutrition. Clearly, Rich believes the company is also a good choice for investors looking to get in on the revolutionary plant-based stock trend.

What do you think? Is BABY a good play? Will it hit $1.00 in the next month? Let us know your take!

Featured image: DepositPhotos © zmijak

Please See Disclaimer

If You Liked This Article Click To Share


1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Else Nutrition Holdings Inc. Bitrics Markets Group Inc. and/or Iman Consulting Group has or expects to receive $800 Canadian dollars from Market Jar Media Inc. for the creation and distribution of the video.

3) Statements and opinions expressed are the opinions of the author and not Bitrics Markets Group Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Bitrics Markets Group Inc. for this Article. Bitrics Markets Group Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Bitrics Markets Group Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Bitrics Markets Group Inc. relies upon the authors to accurately provide this information and Bitrics Markets Group Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Bitrics Markets Group Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Bitrics Markets Group Inc. does not render general or specific investment advice and the information on should not be considered a recommendation to buy or sell any security. Bitrics Markets Group Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on

5) Bitrics Markets Group Inc. and its owners, members, officers, directors, partners and consultants may own shares of the profiled companies, which it may sell at any time, including as soon as it deposits such shares into its trading accounts, during our campaign of the profiled companies stock, after our campaign or at any other time. We also may buy and sell securities in the profiled companies which may cause (a) decline in the price of the profiled companies stock due to our selling activities, (b) increased volatility due to our buying and selling of the profiled companies stock and (c) permit us to make substantial profits while we are profiling each of these companies, yet may result in a diminished value to the stock for investors. for any company mentioned in the Article.